NCT03651856

Atomoxetine for Freezing of Gait in Parkinson's Disease

A Pilot Study of Atomoxetine for Freezing of Gait in Parkinson's Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Medical University of South Carolina · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Subjects are being asked to participate in this study to determine the safety and effectiveness of a drug called atomoxetine in the treatment of freezing of gait for Parkinson's Disease patients. Atomoxetine (ATM) is an approved drug currently on the market for the treatment of attention deficit. It works to increase the amount of norepinephrine (a chemical in the brain that helps keep us awake and alert) in our brain. ATM has not been approved by the Food and Drug Administration (FDA) to be used in the treatment of PD, but has been found to be well tolerated in this patient population.

Conditions

• Parkinson's Disease
• Freezing of Gait

Interventions

Type	Name	Description
DRUG	ATM FOG in PD	open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait

Timeline

• Start date: 2013-01-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2018-08-29
• Last updated: 2018-11-28
• Results posted: 2018-11-28

Locations

1 site across 1 country: United States